Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus–related cirrhosis

Patel, Derek; Terrault, Norah A.; Yao, Francis Y.; Bass, Nathan M.; Ladabaum, Uri

doi:10.1016/s1542-3565(04)00443-4

Cited by 76 publications

(55 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…0.73) adopted for compensated (0.75) and decompensated cirrhosis (0.66), calculated to approximate the average clinical course. A similar assumption was made by Patel and colleagues 307 in their cost-effectiveness analysis of surveillance for HCC among patients with HCV-related cirrhosis. No account was taken of any diminished quality of life that may accompany HCC recurrence, which is relatively common following resection (see the section 'Treatment for hepatocellular carcinoma', p. 7).…”

Section: Postresectionmentioning

confidence: 63%

“…[304][305][306][307][308][309] Three were considered to have less relevance to the project scope and policy context of surveillance for HCC in the current NHS. 305,308 One of these, the oldest (published in 1992), is not strictly a cost-effectiveness analysis and was restricted to people with HBV-related cirrhosis.…”

Section: Cost-effectiveness Of Surveillancementioning

confidence: 99%

“…304,306,307 All were published since 2003 and appear to have been conducted to good modelling standards The present analysis was compared with these three studies. Compared with no surveillance, the incremental costeffectiveness of 6-monthly screening with both AFP tests and ultrasound was between US $24,500 306 and $46,600 307 per QALY (equivalent to between £18,400 and £37,300, if inflated and converted to 2005 UK pounds).…”

Section: Cost-effectiveness Of Surveillancementioning

confidence: 99%

“…Although this is not the first modelling analysis to simulate tumours of different size (e.g. see Arguedas and colleagues 304 and Patel and colleagues 307 ), we believe that this is the first to simulate the likely impact of different tumour sizes on screening test performance, the likelihood of symptomatic/incidental diagnosis and the treatability of detected HCC tumours by either liver resection or transplantation.…”

Section: Strengths and Weaknesses Of The Study Strengths Of The Evalumentioning

confidence: 99%

“…It was also assumed that there is no excess mortality associated with compensated liver cirrhosis, which differs from two previously published cost-effectiveness analyses. 306,307 Costing was conducted using a pragmatic costing approach from an NHS perspective. In adopting an NHS perspective we acknowledge that this ignores some costs to patients and their families that would inevitably follow from taking part in the surveillance programme.…”

Section: Limitations Of the Assessmentmentioning

confidence: 99%

See 4 more Smart Citations

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

150

108

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: K Stein received an unrestricted grant from Schering Plough (UK) to carry out work on the cost-effectiveness of combination therapy for hepatitis C in 2000. KS is also a member of the editorial board for Health Technology Assessment, but he was not involved in the editorial process for this report. M Cramp sits on hepatitis C advisory boards for Schering Plough, Gilead and Roche. He has received unrestricted educational grants from Roche and Schering Plough to support research and service development. He has been awarded an NHS R&D grant looking at injecting drug users who do not have hepatitis C virus infection. J Thompson Coon received a grant from the Hepatitis C Trust to conduct a systematic review of complementary and alternative therapies for the treatment of chronic hepatitis C. HTA Published September 2007This report should be referenced as follows: NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, man...

show abstract

Section: Postresectionmentioning

confidence: 63%